Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a ...

Centhaquine, a new medication to treat patients who have severe blood or fluid loss, significantly improved outcomes and reduced death rate when added to standard of care, compared to standard care ...

KANSAS CITY, Mo.--(BUSINESS WIRE)--Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and hemorrhagic ...

Septic shock results in approximately 350,000 deaths in the U.S. each year, the leading cause of hospital-related mortality and a major financial burden for the medical system Six trial sites with ...

Hemorrhagic shock can occur after losing a significant amount of blood. Both internal and external bleeding can cause it. Hemorrhagic shock is life threatening and requires immediate medical attention ...

Hypovolemia is the most common cause of circulatory failure in children (1). When inadequate tissue perfusion is not recognized and treated rapidly, critical tissue hypoxia may develop, leading to ...

Shock is a medical emergency. It is a condition wherein the blood flow to the various parts of the body drastically reduces. When the organs and tissues of the body become deprived of the needed ...

Goal of the study: The third generation of unbalanced hydrxyethyl starch (HES) (130/04) (Voluven®) shows favorable physicochemical properties and avoids negative effects on coagulation Recently, ...

KANSAS CITY, Mo., Sept. 3, 2024 /PRNewswire/ -- Vivacelle Bio, a late-stage biopharma company developing life-saving treatments for shock and trauma, today announced that it has enrolled the first ...

KANSAS CITY, Mo., Feb. 10, 2023 /PRNewswire/ -- Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and ...